drugset / Trial / NCT04529265

Methylene Blue and Postoperative Neurocognitive Disorders

NCT04529265

Completed 314 enrolled Fudan University
RandomizedParallel-groupDouble-blindPrevention

Summary

Postoperative Neurocognitive Disorders are the most common neurological complications after major surgery, which are associated with higher increased mortality and morbidity in elderly patients undergoing major surgery. Until now highly effective intervention has not been established yet. Recent preclinical studies suggest neuroinflammation may be linked to pathogensis of (postoperative delirium) POD and postoperative cognitive dysfunction (POCD). As Methylene blue(MB) has neuroprotective and anti-inflammatory properties, and it is a safe drug with long history of clinical use, we propose that inflammation-targeted interventions may be useful to prevent POD/POCD in surgical patients.

Timeline

Start
2021-05-01
Primary completion
2023-04-30
Completion
2024-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylene Blue Diagnostic / imaging agent 1 mg/kg Intravenous

Indications